@article{fce2ca4c94a848c8b8a9d6e158647fb1,
title = "Adults with Cerebral Palsy Require Ongoing Neurologic Care: A Systematic Review",
abstract = "Cerebral palsy (CP) neurologic care and research efforts typically focus on children. However, most people with CP are adults. Adults with CP are at increased risk of new neurologic conditions, such as stroke and myelopathy, that require ongoing neurologic surveillance to distinguish them from baseline motor impairments. Neurologic factors could also contribute to the motor function decline, chronic pain, and chronic fatigue that are commonly experienced by adults with CP. Based on a systematic literature review, we suggest (1) guidelines for neurologic surveillance and neurologist referral and (2) clinical research questions regarding the evolving neurologic risks for adults with CP. ANN NEUROL 2021;89:860–871.",
author = "Smith, {Sarah E.} and Mary Gannotti and Hurvitz, {Edward A.} and Jensen, {Frances E.} and Krach, {Linda E.} and Kruer, {Michael C.} and Msall, {Michael E.} and Garey Noritz and Rajan, {Deepa S.} and Aravamuthan, {Bhooma R.}",
note = "Funding Information: This work was supported by National Institute of Neurological Disorders and Stroke grant F30NS100217 (to S.E.S.), National Institute of General Medical Sciences grant T32GM07200 (to S.E.S), 1R37NS115439 (to F.E.J.), National Institute of Neurological Disorders and Stroke grant R01NS080565 (to F.E.J.), National Institute of Neurological Disorders and Stroke grant 1R01NS106298 (to M.C.K.), and Health Resources and Services Administration/US Department of Health and Human Services Maternal and Child Health Bureau T73 MC11047 (to M.E.M.), the Leadership Education in Neurodevelopmental and Related Disorders Training Program (to M.E.M.), and National Institute of Neurological Disorders and Stroke grant 5K12NS098482‐02 (to B.R.A.). Funding Information: The authors have no conflicts of interest that are relevant to this article. F.E.J. reports grants from Eisai Pharma that are unrelated to this work. M.E.M. reports grants from Teva and support (scientific advisory board/consulting) from the US Department of Defense, US National Health Research Services Administration, PTC Therapeutics, Aeglea, and CoA Therapeutics that are unrelated to this work. Publisher Copyright: {\textcopyright} 2021 American Neurological Association",
year = "2021",
month = may,
doi = "10.1002/ana.26040",
language = "English",
volume = "89",
pages = "860--871",
journal = "Annals of Neurology",
issn = "0364-5134",
number = "5",
}